Premium
The effect of tissue factor concentration on calibrated automated thrombography in the presence of inhibitor bypass agents
Author(s) -
Van VEEN J. J.,
GATT A.,
BOWYER A. E.,
COOPER P. C.,
KITCHEN S.,
MAKRIS M.
Publication year - 2009
Publication title -
international journal of laboratory hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.705
H-Index - 55
eISSN - 1751-553X
pISSN - 1751-5521
DOI - 10.1111/j.1751-553x.2007.01022.x
Subject(s) - tissue factor , thrombin generation , thrombin , coagulation , chemistry , recombinant factor viia , substrate (aquarium) , pharmacology , recombinant dna , activated clotting time , platelet , cardiopulmonary bypass , medicine , anesthesia , biochemistry , biology , ecology , gene
Summary Thrombin generation has been suggested as a method to monitor treatment with factor eight inhibitor bypassing activity (FEIBA ® ) or recombinant FVIIa (rFVIIa). The sensitivity of the assay for individual coagulation factors is dependent on the tissue factor (TF) concentration. An inverse relation between the rFVIIa concentration needed to shorten the clotting time and TF concentration has been shown but the data on thrombin generation are inconsistent. Information on TF concentration in measurements with FEIBA ® is limited. We studied the influence of TF concentration (1 and 5 p m ) on thrombin generation through spiking experiments with rFVIIa and/or FEIBA ® in the plasma of severe haemophilia A patients and after four and three treatment episodes, respectively, using the calibrated automated thrombin generation assay (CAT) in platelet poor plasma. Spiking with FEIBA ® showed a linear relation with the endogenous thrombin potential (ETP)/peak at 1 p m but substrate depletion at 5 p m . Spiking with rFVIIa showed a near linear dose–response relation with the ETP/peak at 1 p m but only a shortening of the initiation phase at 5 p m . Similar effects were present in post‐treatment samples. FEIBA ® acted synergistically with rFVIIa. This suggest a role for CAT in monitoring inhibitor bypass treatment but low TF concentrations are required to avoid substrate depletion with FEIBA ® and to demonstrate the effect of rFVIIa.